Neuphoria Therapeutics Inc (NEUP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Neuphoria Therapeutics Inc (NEUP) has a cash flow conversion efficiency ratio of -0.132x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.87 Million) by net assets ($29.42 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Neuphoria Therapeutics Inc market cap and net worth for the company's overall valuation and market capitalisation.
Neuphoria Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Neuphoria Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Neuphoria Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neuphoria Therapeutics Inc ranked by their cash flow conversion efficiency. Explore NEUP operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dongkuk Refractories & Steel Co. Ltd
KQ:075970
|
0.000x |
|
Aseana Properties Limited
LSE:ASPL
|
0.070x |
|
RIAS A/S
CO:RIAS-B
|
0.130x |
|
Vincit Group Oyj
HE:VINCIT
|
-0.010x |
|
Resonance Health Ltd
AU:RHT
|
0.016x |
|
Nortech Systems Incorporated
NASDAQ:NSYS
|
-0.003x |
|
Atlantis Yatirim Holding AS
IS:ATSYH
|
-0.001x |
|
Passat Société Anonyme
PA:ALXIL
|
0.138x |
Annual Cash Flow Conversion Efficiency for Neuphoria Therapeutics Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Neuphoria Therapeutics Inc from 1999 to 2025. View Neuphoria Therapeutics Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $28.87 Million | $77.23 Million | 2.675x | +418.66% |
| 2024-06-30 | $17.49 Million | $-14.68 Million | -0.839x | -24.91% |
| 2023-06-30 | $14.65 Million | $-9.85 Million | -0.672x | -75.80% |
| 2022-06-30 | $56.91 Million | $-21.75 Million | -0.382x | -141.35% |
| 2021-06-30 | $35.76 Million | $-5.66 Million | -0.158x | +48.54% |
| 2020-06-30 | $8.71 Million | $-2.68 Million | -0.308x | +65.04% |
| 2019-06-30 | $12.39 Million | $-10.91 Million | -0.880x | +27.00% |
| 2018-06-30 | $12.46 Million | $-15.02 Million | -1.206x | -2503.99% |
| 2017-06-30 | $31.09 Million | $-1.44 Million | -0.046x | +90.44% |
| 2016-06-30 | $31.69 Million | $-15.36 Million | -0.485x | -340.76% |
| 2015-06-30 | $24.52 Million | $4.94 Million | 0.201x | +165.79% |
| 2014-06-30 | $42.20 Million | $-12.91 Million | -0.306x | -10.78% |
| 2013-06-30 | $37.79 Million | $-10.44 Million | -0.276x | -148.56% |
| 2012-06-30 | $26.51 Million | $-2.95 Million | -0.111x | +56.82% |
| 2011-06-30 | $30.67 Million | $-7.89 Million | -0.257x | +19.46% |
| 2010-06-30 | $21.64 Million | $-6.92 Million | -0.320x | -11.38% |
| 2009-06-30 | $15.09 Million | $-4.33 Million | -0.287x | -6.59% |
| 2008-06-30 | $20.60 Million | $-5.54 Million | -0.269x | +11.10% |
| 2007-06-30 | $19.25 Million | $-5.83 Million | -0.303x | +35.21% |
| 2006-06-30 | $8.12 Million | $-3.80 Million | -0.467x | -15.05% |
| 2005-06-30 | $8.14 Million | $-3.31 Million | -0.406x | +15.00% |
| 2004-06-30 | $6.24 Million | $-2.98 Million | -0.478x | +13.99% |
| 2003-06-30 | $4.52 Million | $-2.51 Million | -0.556x | -7.28% |
| 2002-06-30 | $5.62 Million | $-2.91 Million | -0.518x | -3.23% |
| 2001-06-30 | $5.20 Million | $-2.61 Million | -0.502x | -79.68% |
| 2000-06-30 | $3.02 Million | $-843.87K | -0.279x | -196.31% |
| 1999-06-30 | $-363.81K | $-105.47K | 0.290x | -- |
About Neuphoria Therapeutics Inc
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disord… Read more